

# Tips & Tricks for Rapid Cancer Reporting System (RCRS)

**October 1, 2021**

*Susanne Kessler, MSM, RHIT, CTR*  
*Cindy Traylor-Richards, CTR*

# Disclosures

- None

# Objectives

- Discuss RCRS User Access
- Demonstrate Uploads & Reports
- Explain Tips for Quicker Navigation
- Understanding Your Data

# Expected Outcomes

- Increased knowledge of
  - Functionality
  - Data availability

# RCRS Library

- User Guide
- Measure Specifications
- Videos
- Notifications

## Library

### ▼ Other Resources

[Tip Sheet - Quick tricks to help you navigate through RCRS](#)

[RCRS Training Video: General Navigation](#)

[RCRS Training Video: How to upload a file](#)

[QM Measure Specifications Summary](#)

[QM Breast Specifications](#)

[QM Colon Specifications](#)

[QM Gastric Specifications](#)

[QM Lung Specifications](#)

[QM Rectum Specifications](#)

[QM Latest Measure Release Updates](#)

[RCRS Training Video: Submission History/Submission Details](#)

[14-Oct 2020: Webinar Video Recording](#)

[RCRS Oct 14 Go Live Powerpoint](#)

[The Rationale for Radiation Oncology Data Items in STORE 2018 webinar](#)

[RCRS go Live Webinar Questions and Responses](#)

[RCRS Training Video - Alerts Report](#)

[RCRS Training Video: Case Log Report](#)

[RCRS Training Video: Quality Measures Report](#)

[RCRS and STORE Webinar Q and A](#)

[STORE 2021 Update Summary](#)

# Overview of Access

- Must be listed on FINs Datalinks Manage Staff Contacts
- Program must add/remove users
- One email address for user even when multiple FINs
- One user ID

# Dashboard

NATIONAL  
CANCER  
DATABASE

☰

Admin View

National Cancer Database

Cindy Traylor-Richa

Welcome,  
Cindy Traylor-Richards

Currently Viewing  
National Cancer Database

DASHBOARD

Home Page

PLATFORM

Upload

Notifications30

ANALYTICS

Operational Reports

RESOURCES

CoC Datalinks

ACCOUNT

My Account

Home Page

Dashboard

CoC Accreditation Measures for Site Visit

Note: report displays data available for the current year - 3, as well as 2 years of subsequent data.

Primary Site	Measure	2016 PR	2017 PR	2018 PR
Breast	BCSRT	87.65%	84.44%	89.16%
	HT	100.00%	95.58%	90.72%
	MASTR	100.00%	100.00%	90.00%
	nBx	93.38%	92.90%	95.97%
Colon	T2RLN	91.67%	95.31%	93.98%
Gastric	G15RLN	80.00%	75.00%	90.00%
Lung	LCT	100.00%	100.00%	100.00%
	LNoSurg	100.00%	91.30%	92.00%

Date

Notifications (Click on Notifications link on the left navigation bar)

6/25/2021ACS and IQVIA 4th of July Holiday Closure – 7/5

6/24/2021RCRS Maintenance Sat 06/26 12AM – 7AM ET

Alert Summary

Note: report displays data available for the latest 3 years.

Non-Conco...  
3 Alerts

Critical  
8 Alerts

Almost Crit...  
9 Alerts

Moderate  
4 Alerts

Low  
8 Alerts

Quality Measures Comparison (DX Year: 2020)

Note: report displays data available for the current year - 1.

Measure Name

12RLN

ACT

BCSRT

G15RLN

HT

LCT

LNoSurg

MAC

MASTR

nBx

RECRCT

All CoC Programs

My Facility

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

# Navigation Panel

DASHBOARD

Home Page

PLATFORM

Notifications 30

ANALYTICS

Operational Reports

RESOURCES

Library

CoC Datalinks

ACCOUNT

My Account

Log out

Primary Site	Measure	2016 PF
Breast	BCSRT	94.40%
	HT	93.50%
	MASTR	89.74%
	nBx	92.48%
Colon	12RLN	95.67%
Gastric	G15RLN	63.64%
Lung	LCT	86.60%
	I NoSur	95.65%

Date

Notifications (Click navigation bar)

6/25/2021 ACS and IQVIA 4th

6/24/2021 RCRS Maintenance

6/23/2021 RCRS Level 1 and I



# Upload

## Facility Details

Name:

City:

State:

PLEASE NOTE: **Longer upload times may be experienced during the month of June due to Call for Data submissions.**

- Only .DAT files are accepted for v18.
- Only XML files are accepted for v21.
- Network Facilities: Files must be submitted within the network child facility.
- Merger Facilities: Files must be submitted at the merger parent facility.
- File must contain one FIN only. Multiple FINs within a file will be rejected.
- FIN in uploaded file must match the facility that has been selected.
- As per NAACCR, v18 record length must equal 4,048.
- In the file name, only one period (before the extension of the file) is permitted. Example: testfile.dat
- In the file name, the only special characters permitted are hyphen (-) and underscore (\_)



Drag and Drop File Here to Upload

-or-

Choose File from Computer

(Max File Size: 150 MB)

## Upload History Report

Sort by:

Date of Upload Descending



Status: All

# Upload History Report

Choose File from Computer

(Max File Size: 150 MB)


## Upload History Report

Sort by:


Date of Upload Descending

Status All

Date of Upload



to



Reset

Filter



04/14/2021  
08:13:14  
AM

Receipt Id: **815722**

Facility: **20000000 IQVIA Submission Test Facility 12828**


Processing Status: **File Upload Completed**

File Name: **CancerUPloader\_20000000\_Create.dat**

Uploader Username:

1/1

[Submission Details Report](#)



04/14/2021  
07:13:15  
AM

Receipt Id: **815664**

Facility: **20000000 IQVIA Submission Test Facility 12828**

Processing Status: **File Upload Completed**

File Name: **CancerUPloader\_20000000\_Create.dat**

Uploader Username:

1/1

[Submission Details Report](#)


# Submission Detail Report

[← Admin View](#)

National Cancer Database  
20000000 IQVIA Submission Test Fac...

Cindy Traylor-Ricl

## Upload Success Report - 20000000 IQVIA Submission Test Facility



# Notifications



[← Admin View](#)

Welcome,  
Cindy Traylor-Richards

Currently Viewing  
National Cancer Database

## DASHBOARD

Home Page

## PLATFORM

Upload

Notifications

30

## ANALYTICS

Operational Reports

## Notifications

- 06/25/2021 ACS and IQVIA 4th of July Holiday Closure – 7/5
- 06/24/2021 RCRS Maintenance Sat 06/26 12AM – 7AM ET
- 06/23/2021 **RCRS Level 1 and Level 2 (NCDB) edits**
- 06/17/2021 ACS Juneteenth Holiday Closure – 6/18/2021
- 05/28/2021 RCRS Maintenance Sat 05/29 12AM – 5PM ET
- 05/27/2021 NCDB Call for Data Submission Resource
- 05/26/2021 ACS and IQVIA Memorial Day Closure – 5/31/2021
- 05/12/2021 2021 NCDB Call For Data

# Operational Reports



← Admin View

National Cancer Database

Cindy Traylor-Richards

Welcome,  
Cindy Traylor-Richards

👁 Currently Viewing

National Cancer Database

## DASHBOARD

🏠 Home Page

## PLATFORM

📁 Upload

🔔 Notifications

30

## ANALYTICS

📊 Operational Reports

## Operational Reports

### Cancer Reports



#### Alerts Report

This report provides an overview as well as detailed information regarding cases with outstanding alerts and the associated edit errors.

Note: report displays data available for the latest 3 years.

#### Case Log Report

This report allows users to view a filtered list of cases, along with case-level edits.

Note: report displays data available for the latest 6 years.

#### Quality Measures Report

This report provides details for all quality measures.

Note: report displays data available for the latest 6 years.

#### Comparisons Report

This report allows users to view different performance rates for quality measures and compare the rates from the users' program to the users' program category to all CoC programs.

Note: report displays data available for the latest 6 years.



# Alerts

Run Date/Time: 06/28/2021 02:46:08 PM CDT

Clear Selection Collapse/Expand

▼ Report Description

This report provides an overview as well as detailed information regarding cases with outstanding alerts and the associated edit errors. Note: report displays data available for the latest 3 years.

Alert Summary

Non-Con...  
3 Alerts

Critical  
8 Alerts

Almost ...  
9 Alerts

Moderate  
4 Alerts

Low  
8 Alerts

Alert Summary By Primary Site

Primary Site	Measure	Measure Description	Non-Concordant	Critical	Almost Critical
	BCSRT	Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving	0	4	2

Case List

Alert Message	Acc #
Incomplete Rx data; RT expected to be received within 75 days (365 days following diagnosis)	202002131

Edit Errors

There are no edit errors for the selected case

# Alert Status

Cases are based on # of Days Until Expected Administration of Non-Surgical Therapy

	Alert Status – Based on the # of Days Until Expected Administration of non-Surgical Therapy				
Measure	Low (white/cream)	Moderate (yellow)	Almost Critical (orange)	Critical (red)	Non-concordant (dark red)
BCSRT	≥241	240-181	180-91	≤90	Past due
MAC	≥91	90-61	60-31	≤30	Past due
HT	≥211	210-151	150-76	≤75	Past due
MASTR	≥241	240-181	180-91	≤90	Past due
ACT	≥91	90-61	60-31	≤30	Past due
12RLN	No Alerts for Colon 12 RLNs				

# Alert Status

Cases are based on # of Days Until Expected Administration of Non-Surgical Therapy

	Alert Status – Based on the # of Days Until Expected Administration of non-Surgical Therapy				
Measure	Low (white/cream)	Moderate (yellow)	Almost Critical (orange)	Critical (red)	Non-concordant (dark red)
BCSRT	≥241	240-181	180-91	≤90	Past due
MAC	≥91	90-61	60-31	≤30	Past due
HT	≥211	210-151	150-76	≤75	Past due
MASTR	≥241	240-181	180-91	≤90	Past due
ACT	≥91	90-61	60-31	≤30	Past due
12RLN	No Alerts for Colon 12 RLNs				





# Alerts Reports

Reporting Facility	
Facility ID	
Archive FIN	
Source ID	IQVIA
Acc #	202000223
Seq #	00
Measure Name	HT
Measure Status	S
Measure Description	HT status unknown, administration expected within 365 days ...
Days Remaining	-3
EXCLUSION	
Date of Diagnosis	2020/07/23
Sex	2
Age	54
Class of Case	14
Primary Site	C502
Histology Type ICD-O-3	8500
Behavior Code ICD-O-3	3
CS Tumor Size	
Tumor Size Summary	013
CS Site-Specific Factor 1	
ER Sum	1
ER %	095%
CS Site-Specific Factor 2	
PR Sum	1
PR %	090%
CS Site-Specific Factor 15	
HER2	0
CS Site-Specific Factor 6	
CRM	
CS Site-Specific Factor 25	
Scehma Disc 1	
Grade	
Grade Clin	2
TNM Edition Number	08
TNM Clin T	

# Alerts Reports

RX Date Radiation	2020/10/26
RX Date Rad Ended	2020/12/17
Rad--Location of RX	1
Rad--Regional RX Modality	
ph1 RT MOD	02
ph1 BM TCHQ	01
Rad--Boost RX Modality	
Rad--Treatment Volume	
ph1 RT VOL	40
Reason for No Radiation	0
RX Summ--Hormone	88
RX Date Hormone	
RX Summ--BRM	00
Rx Date BRM	
Rx Date Systemic	
VITAL ST	1
Date First Contact	2020/07/23
Date Last Contact	2021/04/20
Update	2021/06/23 10:41:11 AM

# Alerts Reports

Case Identification	
MRN #	
Patient Name	

Patient Characteristics	
Date of Birth / Age	1965/12/12 / 054
Gender	?

Tumor Characteristics	
Diagnosis Date	2020/07/23
Primary Site	C502
Histology	8500
Surg Diag Staging Proc	02
Staging proc date	2020/07/23
Behavior	3
Nodes Examined	14
Nodes Positive	01
Tumor Size / Tumor Size Summary	/ 013
ER Status	1
PR Status	1
ER %	095%

Case Identification	
Accession Number	202000223
Sequence #	00
Class of Case	14
Last Contact Date / Vital Status	2021/04/20 / 1
Facility	
Recorded Last Update	2021-06-23
Source ID	IQVIA

AJCC Clinical Stage Group	
Clinical Stage Group	1B
Clinical T	cT1c
Clinical N	cN1
Clinical M	cM0
AJCC Pathologic Stage Group	
Path Stage Group	1A
Path T	pT1c
Path N	pN1a
Path M	cM0

Treatment Summary			
Surgery Date	2020/09/02	Date of most definitive Surgery	2020/09/02
Surgery	22	Surgery at this facility	22
Radiation Reg Modality		Phase I Modality	02
		Phase I Beam Technq	01
Radiation Volume		Phase I Volume	40
Radiation Date	2020/10/26	Reason No Radiation	0
Hormone	88	Hormone Date	
Chemotherapy	00	Chemo Date	
Immunotherapy	00	BRM Date	

# Case Log Reports

File

Accession Number:

Type to search in list

(All) 3943 values

198800340

198800370

198800897

198900547

199000184

199000320

Case Contains Errors:

☒ Yes

☒ No

Primary Site:

Case Log

DX Year	Primary Site	Histology Type ICD-O-3	Date Case Updated	Abstracted By	RCRS Edit	NCDB Edit	Details link
2020	C170	8240	20201118		1	1	<a href="https://irp-us-spotfire.solution">https://irp-us-spotfire.solution</a>
2020	C158	8140	20201214		0	0	<a href="https://irp-us-spotfire.solution">https://irp-us-spotfire.solution</a>
2020	C209	8140	20210513		0	0	<a href="https://irp-us-spotfire.solution">https://irp-us-spotfire.solution</a>
2020	C183	8140	20210105		0	0	<a href="https://irp-us-spotfire.solution">https://irp-us-spotfire.solution</a>

Edit Errors

Acc #	Seq #	Edit	Edit Tag	Edit Message	Primary Site	Histology Type ICD-O-3	DX Year	AI
	00	NCDB	N0909	Addr at DX--State and Addr at DX--Postal Code conflict	C170	8240	2020	W

# Quality Measures

File

Summary Panel

Summary View: Table

Measure Group:

All Measure Groups

Measure:

☒ Breast
 

☒ BCSRT
 ☒ HT
 ☒ MAC
 ☒ MASTRT
 ☒ nBx

☒ Colon
 

☒ 12RLN
 ☒ ACT

Quality Measures

Primary Site	Measure	Measure Description	Label	Rolling Year EPR	2021 Estimated Performance Ra
Breast	BCSRT	Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer	PR/EPR 95% CI Benchmark	90.91%	* Data Not Available
	HT	Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor-positive breast cancer	PR/EPR 95% CI Benchmark	100.00%	100.00% [100.00% - 100.00% 90%
	MAC	Combination chemotherapy or chemo-immunotherapy (if HER2 positive) is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or stage IB - III hormone receptor negative breast cancer	PR/EPR 95% CI Benchmark	100.00%	* Data Not Available
	MASTRT	Radiation therapy is recommended or administered following any	PR/EPR	Data Not	

Measure Eligibility by Case Count

Denominator	2
Numerator	2
Incomplete	1
Not Eligible	2


Case List

Acc#	Seq#	DX Year	Primary Site	Measure
202100007	00	2021	Breast	HT

Quality Measures

Rolling Year EPR

# Quality Measures



# Quality Measures

- **Dark green** represent data where upper confidence interval is equal to or greater than the benchmark. The dark green shade represents cases for years that have been locked, starting from current year – 3 (example, current year = 2020 so 2017 and prior will have darker green).
- **Dark red** represent data where upper confidence interval is less than the benchmark. The dark red shade represents cases for years that have been locked, which is current year – 3 (example, current year = 2020 so 2017 and prior will have dark red)
- **Light green** represents data where upper confidence interval is equal to or greater than the benchmark. The light green shade represents cases for years that are still open and could potentially change, which is current year – 2 (example, current year = 2020 so 2020, 2019 and 2018 will have light green). Light green will change to dark green only when it meets current year – 3 condition, for example if 2018 is light green in 2020, it will change to dark green when we get to 2021.
- **Light red** represents data where upper confidence interval is equal is less than the benchmark. The light red shade represents cases for years that have are still open and could potentially change, which is current year – 2 (example, current year = 2020 so 2020, 2019 and 2018 will have light red). Light red will change to dark red only when it meets current year – 3 condition, for example if 2018 is light green in 2020, it will change to dark green when we get to 2021.



# Quality Measures

**Summary Panel**

Summary View: Table

Measure Group: All Measure Groups

Measure:

- ☒ Breast
  - ☒ BCSRT
  - ☒ HT
  - ☒ MAC
  - ☒ MASTRT
  - ☒ nBx
- ☒ Colon
  - ☒ 12RLN
  - ☒ ACT

**Quality Measures**

Primary Site	Measure	Measure Description	Label	Rolling Year EPR	2021 Estimated Performance Rate
Breast	BCSRT	Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer	PR/EPR 95% CI Benchmark	90.04%	* Data Not Available
	HT	Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor-positive breast cancer	PR/EPR 95% CI Benchmark	100.00%	100.00% [100.00% - 100.00%] 90%
	MAC	Combination chemotherapy or chemo-immunotherapy (if HER2 positive) is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or stage IB - III hormone receptor negative breast cancer	PR/EPR 95% CI Benchmark	100.00%	* Data Not Available
	MASTRT	Radiation therapy is recommended or administered following any	PR/EPR	Data Not	

**Measure Eligibility by Case Count**

Denominator	2
Numerator	2
Incomplete	1
Not Eligible	2

**Case List**

Acc#	Seq#	DX Year	Primary Site	Measure
202100007	00	2021	Breast	HT

Quality Measures | **Rolling Year EPR**

Click on the tab to Open Rolling Year EPRs

# Quality Measures

The screenshot displays the 'Quality Measures' application interface. On the left, a sidebar contains a 'Summary Panel' with a dropdown menu for 'Measure Group' (set to 'All Measure Groups') and a list of measures including 'Breast', 'Colon', and 'Gastric'. The main area features a table titled 'EPR Measures' with columns: 'Primary Site', 'Measure', 'Measure Description', 'Label', and 'Rolling Year EPR'. Below this table are two panels: 'Measure Eligibility by Case Count' and 'Case List'. A blue arrow points from the 'Summary Panel' to the 'EPR Measures' table header. The bottom of the interface has tabs for 'Quality Measures' and 'Rolling Year EPR'.

File

Collapse/Expand Clear Selection

Run Date/Time: 08/11/2021 01:12:10 PM CDT

Report Description

Summary Panel

Measure Group:  
All Measure Groups

Measure:  
☐ Breast  
☐ Colon  
☐ Gastric

EPR Measures

Primary Site	Measure	Measure Description	Label	Rolling Year EPR
--------------	---------	---------------------	-------	------------------

Measure Eligibility by Case Count

Case List

Select cell(s) from EPR Measures to view the Case Detail

Select bar(s) from Case Details to view the Case List.

Quality Measures Rolling Year EPR

# Rolling Year EPR

Primary Sites	Measure	Treatment Expectation Timeframe (# months)	# of Months Case is Included in Calculations
Breast <ul style="list-style-type: none"> <li>HT</li> <li>BCSRT</li> <li>MASTRT</li> </ul>	Hormone Therapy Radiation Following BCS Radiation following mast with 4 + LNs	12 months	24 months from Diagnosis Date: 12 months to receive treatment + 12 months [365 days] included in the YTD date range
Breast <ul style="list-style-type: none"> <li>ACT</li> </ul> Colon <ul style="list-style-type: none"> <li>MAC</li> </ul>	Adjuvant Chemotherapy	4 months	16 months from Diagnosis Date: 4 months to receive treatment + 12 months [365 days] included in the YTD date range
Colon <ul style="list-style-type: none"> <li>12 RLN</li> </ul> Gastric <ul style="list-style-type: none"> <li>15 RLN</li> </ul>	Removal & examination of regional lymph nodes	0	12 months from Diagnosis Date: 0 months to receive treatment + 12 months [365 days] included in the YTD date range
Lung <ul style="list-style-type: none"> <li>LCT</li> <li>LNoSurg</li> </ul>	Chemotherapy Surgery not 1 <sup>st</sup> course tx for cN2 M0 lung cases	0	12 months from Diagnosis Date: 0 months to receive treatment + 12 months [365 days] included in the YTD date range
Rectal <ul style="list-style-type: none"> <li>RECTCT</li> </ul>	Chemotherapy and radiation	0	12 months from Diagnosis Date: 0 months to receive treatment + 12 months [365 days] included in the YTD date range
Breast <ul style="list-style-type: none"> <li>nBx</li> </ul>	Needle bx to primary site	0	12 months from Diagnosis Date: 0 months to receive treatment + 12 months [365 days] included in the YTD date range

# Quality Measures Reports

## Case Detail Report

ph1 BM TCHQ	00
Rad--Boost RX Modality	
Rad--Treatment Volume	
ph1 RT VOL	00
Reason for No Radiation	1
RX Summ--Hormone	88
RX Date Hormone	
RX Summ--BRM	00
Rx Date BRM	
Rx Date Systemic	
VITAL ST	1
Date First Contact	2021/04/26
Date Last Contact	2021/05/21
Update	2021/06/3 11:08:14 PM


## Treatment Summary

Case Identification	
Accession Number	
Sequence #	00
Class of Case	14
Last Contact Date / Vital Status	2021/05/21 / 1
Facility	
Recorded Last Update	2021-06-03

AJCC Clinical Stage Group	
Clinical Stage Group	2A
Clinical T	cT2


# Comparison Report

## Comparisons Report -




# Comparison Report

## Comparisons Report -



# Export



# Take Away Points

- Why No Cases in Alerts ?
  - Abstracting timeliness
  - Process of coding pending treatment
  - Review cases submitted to RCRS



# Take Away Points


- Alerts/QMs Not Updating
- Check date of last upload against date the data was last uploaded
  - Was this case included in the upload?
- Uploaded cases must process
  - ~72 hrs after submission to reflect changes
  - Additional time may be needed during heavy submission times
    - End of month
    - Call for Data open time window
- Are there Duplicates
  - Check Case Log

# Take Away Points

- ER/PR negative
  - ER/PR Summary coded to 0 (Negative)
  - Case showing on breast HT measure
- Review Treatment Summary/Review Details link
- Check data item ER/PR Percent Positive or Range
  - If % is coded to a positive % (001) then eligible

# Take Away Points

14	Hormone Receptor Positive	CS Site Specific Factor 1 (ER - Estrogen Receptor)	<i>For Dx Year ≤2017:</i> Estrogen Receptor ( <i>ssf1</i> ) = 10, 30 <b>OR</b> Progesterone Receptor ( <i>ssf2</i> ) = 10, 30
		CS Site Specific Factor 2 (PR - Progesterone Receptor)	
		Estrogen Receptor Percent Positive or Range	<i>For Dx Year ≥2018:</i> ER Percent Positive or Range = 001-100, R10-R99 <b>OR</b> PR Percent Positive or Range = 001-100, R10-R99
		Progesterone Receptor Percent Positive or Range	



Note: \*It is assumed that if a patient received neo-adjuvant chemo/BRM and they are ER/PR+ they should receive hormone therapy independent of tumor size.

24

HT – Breast measure: Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or Stage IB -Stage III hormone receptor positive breast cancer  
 Copyright 2020 American College of Surgeons, Commission on Cancer

# Take Away Points

- Incomplete Case
  - Incomplete Tumor Characteristics
    - Incomplete staging
- Suspense Case
  - Pending receipt of or decision for adjuvant tx
  - Does not apply to BCSRT measure

# Take Away Points

- Changing view
  - Click, hold, and drag
  - Maximize: Hover mouse in right corner of blue banner for outward arrows
  - Minimize: Hover mouse in middle of blue banner for inward arrows

# Contact Information

Questions regarding data:

[NCDB@facs.org](mailto:NCDB@facs.org)

Questions regarding RCRS  
functionality:

[ACSTechSupport@iqvia.com](mailto:ACSTechSupport@iqvia.com)

